Corvus Pharmaceuticals, Inc. — Director's Dealing 2026

Jan 30, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2026-01-28

Reporting Person: Thompson Peter A. (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-28	Common Stock	M	30000	$15.00	Acquired	30000	Direct
2026-01-28	Common Stock	M	15000	$9.70	Acquired	45000	Direct
2026-01-28	Common Stock	M	15000	$12.50	Acquired	60000	Direct
2026-01-28	Common Stock	M	15000	$3.61	Acquired	75000	Direct
2026-01-28	Common Stock	M	15000	$2.00	Acquired	90000	Direct
2026-01-28	Common Stock	M	15000	$3.27	Acquired	105000	Direct
2026-01-28	Common Stock	M	15000	$2.74	Acquired	120000	Direct
2026-01-28	Common Stock	M	15000	$2.60	Acquired	135000	Direct
2026-01-28	Common Stock	M	15000	$0.9899	Acquired	150000	Direct
2026-01-28	Common Stock	M	15000	$0.965	Acquired	165000	Direct
2026-01-28	Common Stock	M	15000	$2.49	Acquired	180000	Direct
2026-01-28	Common Stock	M	15000	$1.64	Acquired	195000	Direct
2026-01-28	Common Stock	M	15000	$2.12	Acquired	210000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-28	Stock Option (Right to Buy)	$15.00	M	30000	Disposed	2026-03-22	Common Stock (30000)	Direct
2026-01-28	Stock Option (Right to Buy)	$9.70	M	15000	Disposed	2027-06-08	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$12.50	M	15000	Disposed	2028-06-21	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$3.61	M	15000	Disposed	2029-06-20	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$2.00	M	15000	Disposed	2030-03-19	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$3.27	M	15000	Disposed	2030-06-09	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$2.74	M	15000	Disposed	2031-06-15	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$2.60	M	15000	Disposed	2031-09-09	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$0.9899	M	15000	Disposed	2032-06-15	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$0.965	M	15000	Disposed	2032-08-11	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$2.49	M	15000	Disposed	2033-06-15	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$1.64	M	15000	Disposed	2033-12-06	Common Stock (15000)	Direct
2026-01-28	Stock Option (Right to Buy)	$2.12	M	15000	Disposed	2024-06-13	Common Stock (15000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8609091	Indirect

Footnotes

F1: Pursuant to an agreement with OrbiMed Advisors LLC ("OrbiMed Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F2: These securities are held of record by OPI V. GP V is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.

F3: Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

F4: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.

F5: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F6: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F7: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F8: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.

F9: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F10: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F11: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.

F12: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F13: The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F14: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

F15: The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F16: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.